Close Menu

Tekmira

The National Institutes of Health this month awarded roughly $1.4 million in grant money to researchers at the University of Texas and Tekmira Pharmaceuticals to support their development of a single RNAi-based drug that can treat both Ebola virus and Marburg virus infections.

Tekmira Pharmaceuticals this week announced that it has received a fast track designation for its phase I Ebola virus drug TKM-Ebola from the US Food and Drug Administration.

Tekmira Pharmaceuticals has appointed Peggy Phillips to its board of directors.

Tekmira Pharmaceuticals this week announced that it has received a $14.5 million milestone payment from Monsanto under the terms of a technology and intellectual property option deal.

Tekmira Pharmaceuticals this week announced that it has signed a deal giving ag-bio firm Monsanto the option to license its proprietary lipid-based RNAi delivery technology for use in agricultural applications.

Tekmira Pharmaceuticals this week announced that it has dosed the first patients in a phase I trial of its next-generation Ebola virus drug TKM-Ebola.

Should Dicerna Pharmaceuticals complete its planned initial public offering, the company would be the first RNAi drug developer to go public since Alnylam Pharmaceuticals did so in 2004.

Tekmira Pharmaceuticals has appointed Michael Abrams as its chief discovery officer, in charge of drug-discovery efforts at the company.

As the development of RNAi-based therapeutics has advanced during 2013, each of the major publically traded companies in the field has seen significant increases in both stock price and, more importantly, market capitalization.

Tekmira Pharmaceuticals said this week that it has received clearance from the US Food and Drug Administration to begin phase I testing of an improved formulation of its RNAi-based Ebola virus drug TKM-Ebola.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.